AxoGen (NASDAQ:AXGN) outlined its strategy to expand peripheral nerve repair adoption and improve profitability following the ...
To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...
Data from a major U.S. clinical trial from the Alliance for Clinical Trials in Oncology has uncovered a genetic factor that ...
Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function The Mount Sinai Hospital is ranked ...
Detailed price information for Angiodynamics Inc (ANGO-Q) from The Globe and Mail including charting and trades.
Hearing the words “you have cancer” is uniquely frightening and devastating, and those life-altering words are spoken to ...
The University of Cambridge is developing a blood test that could detect a common cancer that kills 12,000 people each year.
Scott Adams, the creator of the "Dilbert" comics, has died less than eight months after he announced he had been diagnosed ...
Prostate cancer causes around 12,000 deaths each year but the available tests are unreliable according to experts ...
Research from the University of Cambridge may be able to start a national screening programme for the common cancer ...
Not only can this cause dryness and discomfort, the urethra sometimes doesn’t seal properly, and bacteria can get into the ...
Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback